Understand the source comparison
Cerebrolysin Oral vs Injectable: Comparison
The table below contrasts the two delivery routes across bioavailability, clinical evidence, and practical usability. Injectable (IM/IV) High. Intact peptides reach systemic circulation and cross BBB via receptor-mediated transcytosis 18+ RCTs in stroke, TBI,
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The table below contrasts the two delivery routes across bioavailability, clinical evidence, and practical usability.
- Injectable (IM/IV)
- High. Intact peptides reach systemic circulation and cross BBB via receptor-mediated transcytosis
- 18+ RCTs in stroke, TBI, dementia with positive outcomes; Cochrane reviews confirm modest efficacy
- BDNF/NGF receptor binding, anti-apoptotic signaling, synaptic plasticity enhancement
- Moderate. Requires IM injection technique and refrigerated storage
- Only validated route. All published neuroprotection data come from injectable administration
- Oral (capsules/tablets)
- Zero. Peptides degraded by gastric acid and pancreatic proteases before absorption
- No peer-reviewed RCTs; no pharmacokinetic studies showing CNS penetration
- None. Peptide structure destroyed before CNS exposure
- High. Swallow a capsule
- Not pharmacologically equivalent. No mechanism for intact peptide delivery to the brain